Safety Study of the Bispecific T-Cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL - Related Studies

Safety Study of the Bispecific T-Cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

This study is currently recruiting participants.

Study NCT00274742. Last updated on August 11, 2008. Information provided by Micromet AG

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Non-Hodgkin's Lymphoma, Relapsed

2	Additional conditions recognized in this trial
		Lymphoma
		Lymphoma, Non-Hodgkin

3	More general conditions related to this trial
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type

4	Interventions listed in this trial
		Blinatumomab (MT103)

5	Sponsors listed in this trial
		Micromet AG